REGENXBIO Launches a Manufacturing Facility for Developing Gene Therapies Based on NAV-Technology


  • REGENXBIO plans to construct a cGMP manufacturing facility in Rockville, Maryland to produce gene therapy vectors based on NAV technology at scales up to 2,000L using its platform suspension cell culture process
  • The addition of new cGMP manufacturing facility complements current external manufacturing capabilities, enabling a supply of NAV vectors from both internal and external sources meeting global regulatory requirements and is expected to be operational in 2021
  • REGENXBIO’s NAV technology is a gene delivery platform contains an exclusive right to 100+ novel AAV vectors including AAV7, AAV8, AAV9 and AAVrh10 and is used to develop therapies for multiple indications

Click here to read full press release/ article | Ref: REGENXBIO | Image: Solebury Trout Access